Study on targeted nanoparticles for anticancer therapy

CHEN Ting; LU Ying

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

The delivery of chemotherapeutics with targeted nanoparticles in anticancer therapy was a rapidly growing area of research. The advantages of targeted nanoparticles for drug delivery include water solubility increasement, tumor-specific accumulation and antitumor efficacy improvement, and nonspecific toxicity reduction. Current research in this field focused on understanding precisely how small molecules were released from nanoparticles and deliver to the targeted tumor tissues or cells, and how the unique biodistribution of the drug-carrying nanoparticles limits toxicity in major organs. The existing nanoparticles for the delivery of small-molecule anticancer agents and recent advances in this field were discussed in this paper.

Study on targeted nanoparticles for anticancer therapy

Department of Pharmaceutics,School of Pharmacy,Second Military Medical University, Shanghai 200433,China

Received Date: 2011-04-09

Rev Recd Date: 2011-05-08

Key words:

Abstract: The delivery of chemotherapeutics with targeted nanoparticles in anticancer therapy was a rapidly growing area of research. The advantages of targeted nanoparticles for drug delivery include water solubility increasement, tumor-specific accumulation and antitumor efficacy improvement, and nonspecific toxicity reduction. Current research in this field focused on understanding precisely how small molecules were released from nanoparticles and deliver to the targeted tumor tissues or cells, and how the unique biodistribution of the drug-carrying nanoparticles limits toxicity in major organs. The existing nanoparticles for the delivery of small-molecule anticancer agents and recent advances in this field were discussed in this paper.

HTML

Reference (13)

[1]	Dreher MR, Liu W, Michelich CR, et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers[J]. Natl Cancer Inst,2006,98(5):335.
[2]	Nomura T, Koreeda N, Yamashita F, et al. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissueisolated tumors[J]. Pharm Res,1998,15(1):128.
[3]	Soundararajan A, Bao A, Phillips WT, et al.[¹⁸⁶Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model [J]. Nucl Med Biol,2009,36(5):515.
[4]	Rosenthal E, Poizot-Martin I, Saint-Marc T, et al. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma[J]. Am J Clin Oncol,2002,25(1): 57.
[5]	Rawat M, Singh D, Saraf S,et al. Nanocarriers: promising vehicle for bioactive[J]. Biol Pharm Bull,2006,29(9):1790.
[6]	Zhan CY, Gu B, Xie C,et al. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect[J]. J Control Release,2010,143(1):136.
[7]	Manchester M,Singh P. Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging[J]. Adv Drug Deliv Rev,2006,58(14):1505.
[8]	Singh P,Destito G,Schneemann A,et al. Canine parvovirus-like particles, a novel nanomaterial for tumor targeting[J]. J Nanobiotechnology,2006,4:2.
[9]	Matsumura Y,Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs[J]. Cancer Res,1986, 46(12):6387.
[10]	Thierry B. Drug nanocarriers and functional nanoparticles: applications in cancer therapy[J]. Curr Drug Deliv,2009,6(4):391.
[11]	Ferrari M. Cancer nanotechnology: opportunities and challenges[J]. Nat Rev Cancer ,2005,5(3): 161.
[12]	Sapra P,Tyaqi P,Allen TM.Ligand-targeted liposomes for cancer treatment[J]. Curr Drug Deliv,2005, 2(4):369.
[13]	Sapra P,Moase EH,Ma J,et al. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for lipo-somal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments[J]. Clin Cancer Res,2004,10(3):1100.[14] Sugano M,Eqilmez NK,Yokota SJ,et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice[J]. Cancer Res.2000, 60,(24):6942.[15] Goren D,Horowitz AT,Zalipsky S, et al. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies[J]. Br J Cancer,1996, 74(11):1749.[16] Heidel JD,Yu Z,Liu JY,et al. Administration in non-human primates ofescalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA[J]. Proc Natl Acad Sci USA,2007,104(14):5715.[17] Karmali PP,Kotamraju VR,Kastantin M,et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors[J]. J Nanomedicine,2009, 5(1): 73.[18] Agemy L,Suqahara KN,Kotamraju VR,et al. Nanoparticle-induced vascular blockade in human prostate cancer[J]. Blood,2010,116(15):2847.[19] Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator[J]. Nat Rev Mol. Cell Biol,2002,3(12):932.[20] Nguyen DX,Bos PD,Massague J. Metastasis: from dissemination to organ specific colonization[J]. Nat Rev Cancer,2009,9(4):274.[21] Garg A,Tisdale AW,Haidari E,et al. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide[J]. Int J Pharm,2009,366(1-2):201.[22] Elazar V,Adwan H,Buerle T,et al. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis[J]. Int J Cancer,2010, 126(7):1749.[23] Galanzha EI, Kim JW,Zhaorov VP.Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in vivo detection and killing of circulating cancer stem cells[J]. J Biophotonics,2009, 2(12):725.[24] Schluep T,Cheng J,Khin KT,et al. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice[J]. Cancer Chemother Pharmacol,2006,57(5):654.[25] Schluep T,Hwang J,Hildebrandt IJ,et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements[J]. Proc Natl Acad Sci USA, 2009,106(27):11394.

Message Board

Study on targeted nanoparticles for anticancer therapy

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views